Acute and chronic respiratory illness represent a substantial proportion of childhood disease burden in the United States. Approximately 16% of admissions to U.S. children's hospitals are secondary to respiratory disease. Significant gaps exist between evidence-based clinical practice guidelines and the health services provided to the nation's youth. Results of the first comprehensive evaluation of outpatient pediatric quality of care found U.S. children on average receive only 46% of recommended care;just 45% of recommended care for asthma was received. No similar data exist for hospitalized children. While this level of adherence to standards for ambulatory care is disturbing, the impact of poor quality of care on hospitalized children, especially those at increased risk for respiratory failure, is likely to have more serious consequences. Our main objectives are to develop a rigorously designed quality of care assessment tool that can be used to examine the degree to which hospitals caring for children are adhering to recommended standards of care for respiratory illness and to determine the feasibility and validity of using administrative data to make these assessments. Specifically, we will use the RAND/UCLA modified Delphi method to develop a quality of care assessment tool for pediatric respiratory illness. We will then use the tool to conduct a detailed assessment of inpatient management for children treated for six respiratory conditions: asthma, bronchiolitis, croup, pneumonia, congenital lung malformations, and cystic fibrosis. The tool developed will be structured to generate quality scores using medical records data. First, we will conduct a detailed assessment of the inpatient management of 3,000 children admitted to three U.S. children's hospitals: Cincinnati Children's Hospital Medical Center, Children's Hospital Los Angeles, and Seattle Children's Hospital and Regional Medical Center. Second, we will examine the comparability of quality scores obtained using medical records versus administrative data for quality measurement. Finally, we will examine the relationship between quality scores and child health related quality of life to outcome-validate our quality assessment tool. This study will result in a rigorously designed, disseminable quality assessment tool that can be used by hospitals treating children for respiratory illness to both track and improve on the quality of care they provide.

Public Health Relevance

The quality of care assessment tool we propose to develop in this study will be the first measurement tool available to rigorously and comprehensively evaluate inpatient pediatric care for children with respiratory illness. Without such measurement tools, it is not possible to assess where deficits exist and how to target efforts to best improve care. This tool will be designed for dissemination and use among all hospitals caring for children nationally.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL088503-05
Application #
8438432
Study Section
Health Services Organization and Delivery Study Section (HSOD)
Program Officer
Taggart, Virginia
Project Start
2009-03-01
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2015-02-28
Support Year
5
Fiscal Year
2013
Total Cost
$253,576
Indirect Cost
$38,978
Name
Seattle Children's Hospital
Department
Type
DUNS #
048682157
City
Seattle
State
WA
Country
United States
Zip Code
98105
Mangione-Smith, Rita; Roth, Carol P; Britto, Maria T et al. (2017) Development and Testing of the Pediatric Respiratory Illness Measurement System (PRIMES) Quality Indicators. Hosp Pediatr 7:125-133
Cannavo, Alessandro; Rengo, Giuseppe; Liccardo, Daniela et al. (2017) ?1-Blockade Prevents Post-Ischemic Myocardial Decompensation Via ?3AR-Dependent Protective Sphingosine-1 Phosphate Signaling. J Am Coll Cardiol 70:182-192
Cannavo, Alessandro; Liccardo, Daniela; Eguchi, Akito et al. (2016) Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases. Nat Commun 7:10877
Thal, David M; Homan, Kristoff T; Chen, Jun et al. (2012) Paroxetine is a direct inhibitor of g protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol 7:1830-9
Brinks, Henriette; Boucher, Matthieu; Gao, Erhe et al. (2010) Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms. Circ Res 107:1140-9
Brinks, Henriette; Koch, Walter J (2010) Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure. Drug Discov Today Dis Mech 7:e129-e134
Bonita, Raphael E; Raake, Philip W; Otis, Nicholas J et al. (2010) Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin Transl Sci 3:14-8